As previously described, conditioning regimens incorporated myeloablative conditioning (MAC) comprising busulfan and cyclophosphamide and reduced-intensity conditioning (RIC) comprising fludarabine and busulfan [18 (link), 19 (link)]. Graft-versus-host disease (GVHD) prophylaxis comprised cyclosporin A, methotrexate, and low dose mycophenolate mofetil. For allo-HSCT recipients with haploidentical donors, rabbit antithymocyte globulin (ATG-G [Genzyme, Cambridge, MA, USA] or ATG-F [Fresenius, Bad Homburg, Germany]) was administered. For those using unrelated donors, ATG-G was applied. T-cell-replete grafts from granulocyte colony-stimulation factor-primed peripheral blood were applied to all patients.
Atg f
Manufactured by Fresenius
Sourced in Germany
The ATG-F is a laboratory equipment product from Fresenius. It is designed to perform specific functions within a laboratory setting. The core function of the ATG-F is to provide the necessary capabilities for laboratory operations, but a detailed description cannot be provided while maintaining an unbiased and factual approach.
Automatically generated - may contain errors
Lab products found in correlation
3 protocols using atg f
1
Conditioning and GVHD Prophylaxis in Allo-HSCT
2
Myeloablative and Reduced Intensity Conditioning for Allo-HSCT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Patients underwent myeloablative or reduced intensity conditioning. All conditioning regimens have been described in a previous study [25 (link)]. Peripheral blood stem cells without ex vivo T-cell depletion were collected from donors treated with rhG-CSF (filgrastim; Kirin, Japan; 5–7.5 μg/kg per day). Prophylaxis for graft-versus-host disease (GVHD) comprised cyclosporine A, methotrexate, and low-dose mycophenolate mofetil. Rabbit antithymocyte globulin (ATG-G; thymoglobulin, Genzyme, Cambridge, MA; 6 mg/kg total dose) or ATG-F (Fresenius, Bad Homburg, Germany; 10 mg/kg total dose) was administered to allo-HSCT recipients using haploidentical donors. However, for allo-HSCT recipients with unrelated donors, the total dose of ATG-G was 6 mg/kg. A small portion of allo-HSCT recipients with human leukocyte antigen–matched sibling donors was treated with ATG-G (total dose, 4.5 mg/kg). Calcineurin inhibitors, corticosteroids, tyrosine kinase inhibitors (eg, ruxolitinib), and methotrexate were used for patients with GVHD.
3
Myeloablative Conditioning for Relapsed/Refractory Hematologic Malignancies
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The details of transplant procedures have been described previously 20 (link) . All patients received myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Intensive conditioning regimen which consisted of cladribine (5mg/m 2 /d IV on days - 12 to -10), cytarabine (2 g/m 2 /d IV on days - 12 to - 10) and BUCY was preferred in patients with relapsed or refractory disease and good physical condition. Other drugs, such as cladribine, etoposide, azacitidine and decitabine were added to the conditioning regimen in a few patients.
Peripheral blood stem cells (PBSCs) and/or bone marrow cells were harvested and then infused without ex vivo T-cell depletion. GVHD prophylaxis consisted of cyclosporin A (CSA), methotrexate, and low-dose mycophenolate mofetil. Rabbit antithymocyte globulin (ATG, Thymoglobulin; Genzyme, Cambridge, MA) at dose of 4.5-10mg/kg total dose was administered to patients receiving URD-HSCTs. For patients receiving haplo-HSCT, ATG was administered at 6-10 mg/kg total dose and anti-T-lymphocyte globulin (ATG-F; Fresenius, Bad Homburg, Germany) was administered at 10-40mg/kg total dose. For patients receiving MSD-HSCT, ATG was administered at 0-10 mg/kg total dose.
Peripheral blood stem cells (PBSCs) and/or bone marrow cells were harvested and then infused without ex vivo T-cell depletion. GVHD prophylaxis consisted of cyclosporin A (CSA), methotrexate, and low-dose mycophenolate mofetil. Rabbit antithymocyte globulin (ATG, Thymoglobulin; Genzyme, Cambridge, MA) at dose of 4.5-10mg/kg total dose was administered to patients receiving URD-HSCTs. For patients receiving haplo-HSCT, ATG was administered at 6-10 mg/kg total dose and anti-T-lymphocyte globulin (ATG-F; Fresenius, Bad Homburg, Germany) was administered at 10-40mg/kg total dose. For patients receiving MSD-HSCT, ATG was administered at 0-10 mg/kg total dose.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!